A Study of Grazoprevir (MK-5172) in Hepatitis C-Infected Male Participants (MK-5172-004)
A Study of Grazoprevir (MK-5172) in Hepatitis C-Infected Male Participants (MK-5172-004)
This multiple dose study will assess the safety, tolerability, pharmacokinetics and
 pharmacodynamics of grazoprevir (MK-5172) in Genotype (GT) 1 and GT3 Hepatitis C virus (HCV)-
 infected participants. The primary hypothesis is that administration of grazoprevir for 7
 days is sufficiently safe and well tolerated in HCV-infected males.
Inclusion Criteria:

 -  Baseline health is stable.

 -  Has a clinical diagnosis of chronic HCV infection.

 Exclusion Criteria:

 -  Has a history of stroke or chronic seizures.

 -  Has a history of cancer.

 -  Has a history of human immunodeficiency virus (HIV) infection.

 -  Has had major surgery, donated blood or participated in another investigational study
 within the past 3 months.